Personal best / specialty research
Retatrutide
Body Composition & Metabolic Support
Experimental triple agonist targeting GLP-1, GIP, and glucagon pathways.
Best positioned as an investigational recomp/cut tool. Because it is not FDA-approved, there is no official consumer dose.
Dosage discussion lanes
- Starting / standard
- No official starting dose. Conservative research discussions often begin at 0.25–0.5 mg weekly only under qualified oversight.
- Personal best / low-activity
- Low-activity users usually should not escalate quickly; 0.25–1 mg weekly discussions are conservative.
- Heavy trainer / athlete
- Heavy trainers may discuss 1–2+ mg weekly ramps, but this remains investigational and muscle retention depends on food and training.
- Timing
- Weekly, same day.
- Cycle
- Often discussed as 12–16 week blocks, then reassess; no established long-term protocol.
- Men vs women
- Smaller users and women generally start lower and hold doses longer.
Watch-outs
GI effects, dehydration, gallbladder/pancreas history, appetite too low, muscle loss if under-fed.
Dose framework only. Do not convert to syringe units until product concentration and reconstitution volume are known. Adjust only with qualified oversight and side-effect tracking.
Educational and comparative only. Not a prescription, medical advice, or instruction to self-administer. Start low, change one variable at a time, and match the compound to the goal. Product formulation, route, concentration, lab work, medical history, medications, and legal/regulatory status change the plan.